Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Epigenomics AG (OTC: EPGNF).

Full DD Report for EPGNF

You must become a subscriber to view this report.


Recent News from (OTC: EPGNF)

Epigenomics AG 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Epigenomics AG in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: March, 27 2018 14:37
Epigenomics' (EPGNF) CEO Gregory Hamilton on Q4 2017 Results - Earnings Call Transcript
Epigenomics AG (EPGNF) Q4 2017 Earnings Conference Call March 23, 2018, 09:30 ET Executives Peter Vogt - VP, Corporate Communications & IR Gregory Hamilton - CEO Analysts Simon Scholes - First Berlin Equity Bruce Jackson - Lake Street Capital Markets Marietta Miemiet...
Source: SeekingAlpha
Date: March, 23 2018 15:14
Epigenomics AG 2017 Q3 - Results - Earnings Call Slides
The following slide deck was published by Epigenomics AG in conjunction with their 2017 Q3 earnings Read more ...
Source: SeekingAlpha
Date: November, 16 2017 22:27
Epigenomics' (EPGNF) CEO Gregory Hamilton on Q3 2017 Results - Earnings Call Transcript
Epigenomics AG (EPGNF) Q3 2017 Earnings Conference Call November 15, 2017 08:30 AM ET Executives Peter Vogt - Vice President of Corporate Communications & Investor Relations Greg Hamilton - Chief Executive Officer Analysts Simon Scholes - First Berlin Equity Research Ma...
Source: SeekingAlpha
Date: November, 15 2017 10:56
DGAP-News: Epigenomics AG: Appointment of Director Reimbursement and Medical Affairs
DGAP-News: Epigenomics AG: Appointment of Director Reimbursement and Medical Affairs
Source: OTC Markets
Date: November, 08 2017 00:00
DGAP-News: Supervisory Board of Epigenomics AG Appoints Dr. Jorge Garces as President and Chief Scientific Officer
DGAP-News: Supervisory Board of Epigenomics AG Appoints Dr. Jorge Garces as President and Chief Scientific Officer
Source: OTC Markets
Date: November, 05 2017 00:00
DGAP-News: Epigenomics AG issues convertible bonds
DGAP-News: Epigenomics AG issues convertible bonds
Source: OTC Markets
Date: September, 08 2017 00:00
DGAP-News: Epigenomics Commences Post Approval Study on Epi proColon(R)
DGAP-News: Epigenomics Commences Post Approval Study on Epi proColon(R)
Source: OTC Markets
Date: August, 30 2017 00:00
Epigenomics' (EPGNF) CEO Gregory Hamilton on Q2 2017 Results - Earnings Call Transcript
Epigenomics AG (EPGNF) Q2 2017 Earnings Conference Call August 9, 2017 10:00 AM ET Executives Peter Vogt - VP of Corporate Communications & IR Gregory Hamilton - Chief Executive Officer Analysts Marietta Miemietz - equinet Bank AG Wilhelm Zours - Deutsche Balaton AG S...
Source: SeekingAlpha
Date: August, 12 2017 01:17
Epigenomics AG Announces 2017 Second Quarter and Six Months Financial Results
Epigenomics AG Announces 2017 Second Quarter and Six Months Financial Results
Source: OTC Markets
Date: August, 10 2017 00:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-14N/A2.83N/AN/A0
2018-08-13N/A2.83N/AN/A0
2018-08-10N/A2.83N/AN/A0
2018-08-092.832.832.832.837,100
2018-08-08N/A2.70N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-092,5007,10035.2113Short
2018-07-251,0001,000100.0000Short
2018-07-061,0001,000100.0000Short
2018-06-193,70020,39818.1390Cover
2018-06-122,0004,05049.3827Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EPGNF.


About Epigenomics AG (OTC: EPGNF)

Logo for Epigenomics AG (OTC: EPGNF)

Epigenomics is a molecular diagnostics company focused on blood based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics lead product, Epi proColon, is a blood based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration FDA and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics second product, Epi proLung, is in development as a blood based test for lung cancer detection. For more information, visit www.epigenomics.com.

 

Contact Information

 

 

Current Management

  • Heino von Prondzynski / Chairman of the Supervisory Board
  • Gregory Hamilton / CEO
  • Dr. Uwe Staub / COO
  • Peter Vogt / VP, Corp. Comm., IR
  • Ann Clare Kessler, Ph.D. /
  • Prof. Gunther Reiter /

Current Share Structure

  • Market Cap: $120,071,800 - 03/09/2018
  • Authorized: 24,014,360 - 10/12/2017
  • Issue and Outstanding: 24,014,360 - 10/12/2017

 


Recent Filings from (OTC: EPGNF)

Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: January, 09 2018
Semi-Annual Report - 2017 Semi-Annual Report
Filing Type: Semi-Annual Report - 2017 Semi-Annual ReportFiling Source: OTC Markets
Filing Date: August, 10 2017
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: May, 10 2017
Annual Report - Annual Report
Filing Type: Annual Report - Annual ReportFiling Source: OTC Markets
Filing Date: April, 26 2017
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: November, 09 2016
Semi-Annual Report - Semi-Annual Report
Filing Type: Semi-Annual Report - Semi-Annual ReportFiling Source: OTC Markets
Filing Date: August, 30 2016
Quarterly Report - Quarterly Report - Q1 Report 2016
Filing Type: Quarterly Report - Quarterly Report - Q1 Report 2016Filing Source: OTC Markets
Filing Date: May, 24 2016
Annual Report - Annual Report
Filing Type: Annual Report - Annual ReportFiling Source: OTC Markets
Filing Date: March, 18 2016
Quarterly Report - 9-Month Report
Filing Type: Quarterly Report - 9-Month ReportFiling Source: OTC Markets
Filing Date: December, 03 2015

 

 


Daily Technical Chart for (OTC: EPGNF)

Daily Technical Chart for (OTC: EPGNF)


Stay tuned for daily updates and more on (OTC: EPGNF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: EPGNF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EPGNF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of EPGNF and does not buy, sell, or trade any shares of EPGNF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/